Clinical Trials Logo
  1. Home
  2. Irritable Bowel Syndrome
  3. NCT02079857
  4. Details
NCT02079857 Clinical Trial

Symptom Management for Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

Official title:
Symptom Management for Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02079857
Other study ID # 12-02325
Secondary ID R01NR013695
Status Completed
Phase N/A
First received
Last updated
Start date November 2012
Est. completion date November 1, 2019

Study information
Verified date July 2020
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to test the efficacy of a symptom management treatment strategy, Acupuncture/Moxibustion (Acu/Moxa), to improve the symptoms associated with Irritable Bowel Syndrome (IBS) in adults.

Recruitment information / eligibility
Status Completed
Enrollment 183
Est. completion date November 1, 2019
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Men and women 18 to 70 years of age.

- Diagnosis of IBS based on ROME III criteria.

- Complete symptom diaries and return completed diaries at all sessions.

Exclusion Criteria:

- History of co-existing gastrointestinal, and/or gynecological, and/or urologic pathology.

- Alarm symptoms according to ROME III.

- Individuals currently receiving other types of complementary therapies.

- Individuals with an acute medical condition requiring acute medical attention.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Standard protocol
Subjects will receive a standard treatment
• Individualized protocol
Subjects will receive an individualized treatment
• Sham acupuncture/Placebo moxa
Subjects will receive sham acupuncture/placebo moxa

Locations
Country Name City State
United States NYU Division of Special Studies in Symptom Management New York New York

Sponsors (2)
Lead Sponsor Collaborator
NYU Langone Health National Institute of Nursing Research (NINR)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Symptom severity-abdominal pain week 1
Primary Symptom severity-abdominal pain week 4
Primary Symptom severity-abdominal pain week 8
Primary Symptom severity-abdominal pain week 12
Primary Symptom severity-abdominal pain week 24
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3